Thu, Jul 31, 2025
[Archive]
Volume 15, Issue 3 (6-2025)
Iran J Ped Hematol Oncol 2025, 15(3): 543-553 |
Back to browse issues page
Ethics code: IR.KMU.REC.1396.2228
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Motaghi M, Norouzi A, Chatrabnous N, Jafarzadeh A. Overexpression of the IL-33/ST2 in Pediatric Acute Lymphoblastic Leukemia: Evaluation of the Effects of a Treatment Program. Iran J Ped Hematol Oncol 2025; 15 (3) :543-553
URL: http://ijpho.ssu.ac.ir/article-1-910-en.html
URL: http://ijpho.ssu.ac.ir/article-1-910-en.html
Department of Hematology and Laboratory Sciences, Para-Medicine School, Kerman University of Medical Sciences, Kerman, Iran & Department of Hematology and Laboratory Sciences, Para-Medicine School, Kerman University of Medical Sciences, Kerman, Iran
Abstract: (198 Views)
Background: The study focuses on B-acute lymphoblastic leukemia (B-ALL), a common childhood blood cancer marked by an overproduction of B lymphocytes. It explores the role of cytokine expression changes, particularly Interleukin-33 (IL-33), which has both anti- and pro-tumor effects. The research assesses the expression of IL-33 and its receptor, suppression of tumorigenicity 2 (ST2), in B-ALL patients before and after chemotherapy treatment.
Materials and Methods: In this quasi-experimental investigation, peripheral blood specimens were taken from 33 newly-diagnosed/untreated ALL patients. An induction chemotherapy course was administered to ALL patients for 30 days following diagnosis. Blood samples were taken again after the completion of induction chemotherapy. 30 healthy individuals with matched age and gender were also recruited as a control group. Serum IL-33 quantities were assessed using the ELISA method. Total RNA was extracted from peripheral blood samples, and the gene expression of IL33 and ST2 was measured using real-time PCR.
Results: In B-ALL patients, the pre-treatment serum IL-33 concentrations (33.89 ± 4.38 Pg/mL) were substantially greater than the healthy group (20.66 ± 2.20 Pg/mL, P<0.02). Pre-treatment expression of IL-33 and ST2 mRNA (1.79 ± 0.18 and 1.42 ± 0.18) was also significantly higher than those in the healthy group (1.00 ± 0.10 and 1.00 ± 0.09; P<0.001 and P<0.05, respectively). After chemotherapy, serum IL-33 concentrations (22.40 ± 2.60 Pg/mL) and mRNA expression of IL-33 (0.91 ± 0.15) were significantly reduced compared to pre-treatment levels (P<0.04 and P<0.001, respectively). There were no notable differences in serum IL-33 levels or mRNA expression of IL-33 and ST2 between controls and treated patients (P<0.61, P<0.63, and P<0.48, respectively).
Conclusion: Greater expression of IL-33 and ST2 was observed in B-ALL patients, which were decreased at the end of a therapy course.
Materials and Methods: In this quasi-experimental investigation, peripheral blood specimens were taken from 33 newly-diagnosed/untreated ALL patients. An induction chemotherapy course was administered to ALL patients for 30 days following diagnosis. Blood samples were taken again after the completion of induction chemotherapy. 30 healthy individuals with matched age and gender were also recruited as a control group. Serum IL-33 quantities were assessed using the ELISA method. Total RNA was extracted from peripheral blood samples, and the gene expression of IL33 and ST2 was measured using real-time PCR.
Results: In B-ALL patients, the pre-treatment serum IL-33 concentrations (33.89 ± 4.38 Pg/mL) were substantially greater than the healthy group (20.66 ± 2.20 Pg/mL, P<0.02). Pre-treatment expression of IL-33 and ST2 mRNA (1.79 ± 0.18 and 1.42 ± 0.18) was also significantly higher than those in the healthy group (1.00 ± 0.10 and 1.00 ± 0.09; P<0.001 and P<0.05, respectively). After chemotherapy, serum IL-33 concentrations (22.40 ± 2.60 Pg/mL) and mRNA expression of IL-33 (0.91 ± 0.15) were significantly reduced compared to pre-treatment levels (P<0.04 and P<0.001, respectively). There were no notable differences in serum IL-33 levels or mRNA expression of IL-33 and ST2 between controls and treated patients (P<0.61, P<0.63, and P<0.48, respectively).
Conclusion: Greater expression of IL-33 and ST2 was observed in B-ALL patients, which were decreased at the end of a therapy course.
Type of Study: Research |
Subject:
Oncology
Received: 2024/11/13 | Accepted: 2025/06/20 | Published: 2025/06/20
Received: 2024/11/13 | Accepted: 2025/06/20 | Published: 2025/06/20
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
